Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • Alzheimer’s Disease
    • ALS
    • Parkinson’s Disease
    • Posters & Publications
  • News & Media
    • Press Releases
    • Corporate Presentations
    • Events
    • In The News
    • Videos
    • Commentary
    • Podcasts
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • TSX: PMN
    • OTCQB: ARFXF
    • Analyst Coverage
  • SEDAR
  • SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
May 13, 2020 6:30am EDT

ProMIS Neurosciences Announces First Quarter 2020 Results

May 12, 2020 6:30am EDT

ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for development of a highly accurate COVID-19 antibody test

May 06, 2020 6:30am EDT

ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS

Apr 30, 2020 6:30am EDT

ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases

Apr 22, 2020 2:43pm EDT

ProMIS Neurosciences commends Biogen for clarifying aducanumab regulatory filing

Apr 15, 2020 6:30am EDT

ProMIS Neurosciences announces collaboration to develop serological test to assess COVID-19 immunity

Apr 09, 2020 6:30am EDT

Journal of the American Academy of Neurology Publishes ProMIS Neurosciences’ Abstracts on Novel Antibody Candidates

Apr 07, 2020 6:30am EDT

ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020

Mar 24, 2020 6:30am EDT

PROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING

Mar 18, 2020 6:30am EDT

ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results

  • arrow_back
  • 1…
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …18
  • arrow_forward
  • Email Alerts
  • Contacts
Facebook Linkedin Spotify Twitter
©2022 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy